Linked Life Data

20451663

Source:http://linkedlifedata.com/resource/pubmed/id/20451663

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2010-8-2
pubmed:databankReference
pubmed:abstractText
Patients with moderate to severe Crohn's disease who receive infliximab may experience secondary failure (loss of response and/or hypersensitivity). Data on the utility of switching to certolizumab pegol in these patients are limited.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1542-7714
pubmed:author
pubmed:copyrightInfo
Copyright 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
pubmed:issnType
Electronic
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
688-695.e2
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2010
pubmed:articleTitle
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab.
pubmed:affiliation
Mayo Clinic, Rochester, Minnesota, USA.
pubmed:publicationType
Journal Article, Comparative Study, Randomized Controlled Trial, Multicenter Study